Top MarketRank™ StocksTop MarketRank™NASDAQ:KRYS Krystal Biotech (KRYS) Stock Price, News & Analysis $160.61 +6.56 (+4.26%) Closing price 04:00 PM EasternExtended Trading$159.35 -1.26 (-0.78%) As of 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Krystal Biotech Stock (NASDAQ:KRYS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Krystal Biotech alerts:Sign Up Key Stats Today's Range$155.20▼$160.6950-Day Range$134.94▼$156.9852-Week Range$122.80▼$207.84Volume364,668 shsAverage Volume330,474 shsMarket Capitalization$4.65 billionP/E Ratio32.64Dividend YieldN/APrice Target$209.00Consensus RatingModerate Buy Company Overview Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments. The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition. KB103 has advanced through clinical trials under orphan drug and breakthrough therapy designations granted by the U.S. Food and Drug Administration. In addition to DEB, Krystal Biotech is advancing a second program, KB105, aimed at correcting the genetic defect underlying pseudoxanthoma elasticum. The company maintains an in-house cGMP manufacturing facility to support both development activities and future commercialization efforts. Since its initial public offering on the Nasdaq in July 2019, Krystal Biotech has expanded its clinical and regulatory footprint, enrolling patients in multiple U.S. and international study sites. The company is led by a management team with deep expertise in gene therapy development and regulatory strategy. With a growing pipeline and a dedicated manufacturing infrastructure, Krystal Biotech is positioned to advance its targeted gene therapies through late-stage development and toward potential approval.AI Generated. May Contain Errors. Read More Krystal Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks99th Percentile Overall ScoreKRYS MarketRank™: Krystal Biotech scored higher than 99% of companies evaluated by MarketBeat, and ranked 27th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingKrystal Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialKrystal Biotech has a consensus price target of $209.00, representing about 32.1% upside from its current price of $158.21.Amount of Analyst CoverageKrystal Biotech has only been the subject of 4 research reports in the past 90 days.Read more about Krystal Biotech's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth64.17% Earnings GrowthEarnings for Krystal Biotech are expected to grow by 64.17% in the coming year, from $6.14 to $10.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Krystal Biotech is 32.28, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 281.49.Price to Earnings Ratio vs. SectorThe P/E ratio of Krystal Biotech is 32.28, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 76.77.Price to Book Value per Share RatioKrystal Biotech has a P/B Ratio of 4.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Krystal Biotech's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.81% of the float of Krystal Biotech has been sold short.Short Interest Ratio / Days to CoverKrystal Biotech has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Krystal Biotech has recently decreased by 0.86%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKrystal Biotech does not currently pay a dividend.Dividend GrowthKrystal Biotech does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.87 Percentage of Shares Shorted13.81% of the float of Krystal Biotech has been sold short.Short Interest Ratio / Days to CoverKrystal Biotech has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Krystal Biotech has recently decreased by 0.86%, indicating that investor sentiment is improving. News and Social Media3.9 / 5News Sentiment0.95 News SentimentKrystal Biotech has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Krystal Biotech this week, compared to 8 articles on an average week.Search Interest10 people have searched for KRYS on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows4 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,487,943.00 in company stock.Percentage Held by Insiders13.70% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.29% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Krystal Biotech's insider trading history. Receive KRYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KRYS Stock News HeadlinesKrystal Biotech stock jumps after FDA expands VYJUVEK labelSeptember 16 at 6:29 AM | in.investing.comKrystal Biotech gets expanded FDA approval for VyjuvekSeptember 16 at 6:29 AM | msn.comREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.September 18 at 2:00 AM | Paradigm Press (Ad)FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering SkinSeptember 15 at 2:09 PM | benzinga.comKrystal Biotech announces FDA approval of update VYJUVEK labelSeptember 15 at 11:35 AM | msn.comKrystal Biotech Announces FDA Approval of Updated VYJUVEK® LabelSeptember 15 at 8:00 AM | globenewswire.comKrystal Biotech, Inc. (NASDAQ:KRYS) Given Average Rating of "Moderate Buy" by AnalystsSeptember 13, 2025 | americanbankingnews.com5 Best Stocks To Buy For September 2025September 12, 2025 | forbes.comSee More Headlines KRYS Stock Analysis - Frequently Asked Questions How have KRYS shares performed this year? Krystal Biotech's stock was trading at $156.66 at the beginning of 2025. Since then, KRYS shares have increased by 1.0% and is now trading at $158.2050. How were Krystal Biotech's earnings last quarter? Krystal Biotech, Inc. (NASDAQ:KRYS) announced its quarterly earnings results on Monday, August, 4th. The company reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.21. The firm had revenue of $96.04 million for the quarter, compared to the consensus estimate of $95.42 million. Krystal Biotech had a net margin of 40.85% and a trailing twelve-month return on equity of 15.21%. Read the conference call transcript. When did Krystal Biotech IPO? Krystal Biotech (KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO. Who are Krystal Biotech's major shareholders? Krystal Biotech's top institutional shareholders include State Street Corp (4.68%), Soleus Capital Management L.P. (3.19%), Braidwell LP (2.51%) and Redmile Group LLC (2.29%). Insiders that own company stock include Krish S Krishnan, Suma Krishnan, Daniel Janney, Dino A Rossi, Kathryn Romano, Andrew C Orth and Julian S Gangolli. View institutional ownership trends. How do I buy shares of Krystal Biotech? Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Krystal Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Krystal Biotech investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Last Earnings8/04/2025Today9/18/2025Next Earnings (Estimated)11/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KRYS CIK1711279 Webwww.krystalbio.com Phone(412) 586-5830FaxN/AEmployees210Year Founded2017Price Target and Rating Average Price Target for Krystal Biotech$209.00 High Price Target$245.00 Low Price Target$166.00 Potential Upside/Downside+33.4%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$4.92 Trailing P/E Ratio31.82 Forward P/E Ratio25.52 P/E GrowthN/ANet Income$89.16 million Net Margins40.85% Pretax Margin46.98% Return on Equity15.21% Return on Assets13.81% Debt Debt-to-Equity RatioN/A Current Ratio9.68 Quick Ratio9.33 Sales & Book Value Annual Sales$290.52 million Price / Sales15.61 Cash Flow$4.71 per share Price / Cash Flow33.29 Book Value$32.90 per share Price / Book4.76Miscellaneous Outstanding Shares28,940,000Free Float24,978,000Market Cap$4.54 billion OptionableOptionable Beta0.66 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:KRYS) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Krystal Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.